KINS vs. PBYI
KINS (Kingstone Companies, Inc.) and PBYI (Puma Biotechnology, Inc.) are both stocks. KINS operates in Insurance - Property & Casualty (Financial Services), while PBYI operates in Biotechnology (Healthcare). Over the past 10 years, KINS returned 7.27%/yr vs -15.39%/yr for PBYI. At a 0.06 correlation, their price movements are largely independent.
Performance
KINS vs. PBYI - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, KINS achieves a -9.29% return, which is significantly lower than PBYI's 14.45% return. Over the past 10 years, KINS has outperformed PBYI with an annualized return of 7.27%, while PBYI has yielded a comparatively lower -15.39% annualized return.
KINS
- 1D
- 0.86%
- 1M
- -2.13%
- YTD
- -9.29%
- 6M
- 1.91%
- 1Y
- -2.30%
- 3Y*
- 122.25%
- 5Y*
- 14.73%
- 10Y*
- 7.27%
PBYI
- 1D
- -2.44%
- 1M
- -9.56%
- YTD
- 14.45%
- 6M
- 31.21%
- 1Y
- 105.43%
- 3Y*
- 24.25%
- 5Y*
- -9.60%
- 10Y*
- -15.39%
KINS vs. PBYI - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
KINS Kingstone Companies, Inc. | -9.29% | 11.54% | 613.15% | 57.78% | -72.27% | -22.97% | -11.56% | -54.74% | -3.80% | 39.37% |
PBYI Puma Biotechnology, Inc. | 14.45% | 95.08% | -29.56% | 2.36% | 39.14% | -70.37% | 17.26% | -57.00% | -79.41% | 221.99% |
Correlation
The correlation between KINS and PBYI is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.17 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.09 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.09 |
Correlation (All Time) Calculated using the full available price history since Apr 25, 2012 | 0.06 |
The correlation between KINS and PBYI shifts across timeframes, from 0.06 (all time) to 0.17 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
KINS:
$219.26M
PBYI:
$346.26M
KINS:
-$399.22
PBYI:
$0.48
KINS:
0.00
PBYI:
1.52
KINS:
0.00
PBYI:
2.70
KINS:
$59.92B
PBYI:
$227.21M
KINS:
$100.92M
PBYI:
$169.14M
KINS:
-$6.57B
PBYI:
$46.97M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
KINS vs. PBYI — Risk / Return Rank
KINS
PBYI
KINS vs. PBYI - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Kingstone Companies, Inc. (KINS) and Puma Biotechnology, Inc. (PBYI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| KINS | PBYI | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.57 | ||
| Sortino ratioReturn per unit of downside risk | -1.98 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.35 | -0.32 |
| Calmar ratioReturn relative to maximum drawdown | -0.10 | 4.11 | -4.21 |
| Martin ratioReturn relative to average drawdown | -0.21 | 9.31 | -9.52 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| KINS | PBYI | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.06 | 1.52 | -1.57 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.20 | -0.13 | +0.33 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.12 | -0.19 | +0.31 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.07 | -0.04 | +0.11 |
Drawdowns
KINS vs. PBYI - Drawdown Comparison
The maximum KINS drawdown since its inception was -96.97%, roughly equal to the maximum PBYI drawdown of -99.40%. Use the drawdown chart below to compare losses from any high point for KINS and PBYI.
Loading charts...
Drawdown Indicators
| KINS | PBYI | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.97% | -99.40% | +2.43% |
Max Drawdown (1Y)Largest decline over 1 year | -24.22% | -25.78% | +1.56% |
Max Drawdown (3Y)Largest decline over 3 years | -38.84% | -69.59% | +30.75% |
Max Drawdown (5Y)Largest decline over 5 years | -91.00% | -85.86% | -5.14% |
Max Drawdown (10Y)Largest decline over 10 years | -96.20% | -98.76% | +2.56% |
Current DrawdownCurrent decline from peak | -29.08% | -97.52% | +68.44% |
Average DrawdownAverage peak-to-trough decline | -49.30% | -74.42% | +25.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.82% | 11.36% | -0.54% |
Volatility
KINS vs. PBYI - Volatility Comparison
Kingstone Companies, Inc. (KINS) has a higher volatility of 15.55% compared to Puma Biotechnology, Inc. (PBYI) at 9.68%. This indicates that KINS's price experiences larger fluctuations and is considered to be riskier than PBYI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| KINS | PBYI | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.55% | 9.68% | +5.87% |
Volatility (6M)Calculated over the trailing 6-month period | 28.66% | 41.71% | -13.05% |
Volatility (1Y)Calculated over the trailing 1-year period | 39.74% | 69.92% | -30.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 72.67% | 75.83% | -3.16% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 59.33% | 80.65% | -21.32% |
Dividends
KINS vs. PBYI - Dividend Comparison
KINS's dividend yield for the trailing twelve months is around 1.32%, while PBYI has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
KINS Kingstone Companies, Inc. | 1.32% | 0.59% | 0.00% | 0.00% | 8.89% | 3.20% | 2.74% | 4.19% | 2.26% | 1.61% | 1.82% | 2.36% |
PBYI Puma Biotechnology, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
KINS vs. PBYI - Financials Comparison
This section allows you to compare key financial metrics between Kingstone Companies, Inc. and Puma Biotechnology, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
KINS vs. PBYI - Profitability Comparison
KINS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kingstone Companies, Inc. reported a gross profit of 0.00 and revenue of 59.78B. Therefore, the gross margin over that period was 0.0%.
PBYI - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported a gross profit of 34.40M and revenue of 44.80M. Therefore, the gross margin over that period was 76.8%.
KINS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kingstone Companies, Inc. reported an operating income of 0.00 and revenue of 59.78B, resulting in an operating margin of 0.0%.
PBYI - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported an operating income of -3.83M and revenue of 44.80M, resulting in an operating margin of -8.5%.
KINS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kingstone Companies, Inc. reported a net income of -5.81B and revenue of 59.78B, resulting in a net margin of -9.7%.
PBYI - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Puma Biotechnology, Inc. reported a net income of -3.80M and revenue of 44.80M, resulting in a net margin of -8.5%.
Frequently Asked Questions
KINS and PBYI have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
KINS has higher volatility (15.55%) compared to PBYI (9.68%). In terms of maximum drawdown, KINS dropped -96.97% vs PBYI's -99.40%.
PBYI currently has the higher Sharpe Ratio (1.52 vs -0.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for KINS and PBYI
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer